Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials

被引:29
作者
Hanrahan, EO [1 ]
Hennessy, BT [1 ]
Valero, V [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, Houston, TX 77230 USA
关键词
anthracyclines; breast cancer; complete response; neoadjuvant chemotherapy; pathological; taxanes; trastuzumab;
D O I
10.1517/14656566.6.9.1477
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Neoadjuvant chemotherapy (NAC) is long established as part of the multi-modality management of locally advanced breast cancer or inflammatory breast cancer, leading to significantly improved outcome. Numerous recent studies have compared the use of anthracycline-based NAC with adjuvant chemotherapy in earlier-stage disease, and have shown equivalent disease-free and overall survival rates with increased breast conservation rates. These studies have also shown that a pathological complete response after NAC is associated with improved long-term outcome. More recently, the taxanes have been introduced into clinical trials of NAC with increased overall and pCR rates. However, there is no evidence that the addition of taxanes to neoadjuvant anthracycline-based chemotherapy significantly improves long-term disease free survival or overall survival. This paper reviews these trials, as well as trials of dose-dense and trastuzumab-containing NAC regimens. The review discusses the potential for NAC to replace prolonged adjuvant trials in the assessment of new therapeutic agents (using pathological complete response as a surrogate for long-term outcome), to be used as an in vivo chemosensitivity assay to guide further treatment, and to identify molecular markers that correlate with tumour sensitivity or resistance to chemotherapeutic agents so that the treatment of patients can be individualised.
引用
收藏
页码:1477 / 1491
页数:15
相关论文
共 95 条
  • [41] 2-O
  • [42] Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
    Fossati, R
    Confalonieri, C
    Torri, V
    Ghislandi, E
    Penna, A
    Pistotti, V
    Tinazzi, A
    Liberati, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3439 - 3460
  • [43] Estrogen-receptor-directed neoadjuvant therapy for breast cancer: Results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy
    Gazet, JC
    Ford, HT
    Gray, R
    McConkey, C
    Sutcliffe, R
    Quilliam, J
    Makinde, V
    Lowndes, S
    Coombes, RC
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (05) : 685 - 691
  • [44] Gianni L, 2004, J CLIN ONCOL, V22, p3S
  • [45] GIANNI L, 2005, ASCO ANN M
  • [46] GREEN MC, 2002, P AM SOC CLIN ONC AN, V21
  • [47] GUNDUZ N, 1979, CANCER RES, V39, P3861
  • [48] HARRIS L, 2003, P AM SOC CLIN ONC, V22
  • [49] Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research
    Hayward, RL
    Dixon, JM
    [J]. SURGICAL ONCOLOGY-OXFORD, 2003, 12 (04): : 289 - 304
  • [50] Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    Henderson, IC
    Berry, DA
    Demetri, GD
    Cirrincione, CT
    Goldstein, LJ
    Martino, S
    Ingle, JN
    Cooper, MR
    Hayes, DF
    Tkaczuk, KH
    Fleming, G
    Holland, JF
    Duggan, DB
    Carpenter, JT
    Frei, E
    Schilsky, RL
    Wood, WC
    Muss, HB
    Norton, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 976 - 983